Drug Profile
Methylenedioxymetamfetamine - MAPS Europe B.V.
Alternative Names: ecstasy; MDMA; Methylenedioxymetamphetamine; Methylenedioxymethamfetamine; Methylenedioxymethamphetamine; MidomafetamineLatest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator MAPS Europe B.V.
- Class Amines; Amphetamines; Anxiolytics; Behavioural disorder therapies; Benzodioxoles; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Post-traumatic stress disorders
Most Recent Events
- 12 Feb 2024 Methylenedioxymetamfetamine receives priority review status for Post-traumatic stress disorders in USA
- 10 Feb 2024 FDA assigns PDUFA action date of 11/08/2024 for Methylenedioxymetamfetamine Post-traumatic stress disorders
- 10 Feb 2024 US FDA accepts NDA for Methylenedioxymetamfetamine for Post-traumatic stress disorders for review